Immunitybio Inc (IBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -224,187 | -160,158 | -96,226 | -96,423 | -120,809 |
| Depreciation Amortization | 13,533 | 14,042 | 10,018 | 7,163 | 5,789 |
| Income taxes - deferred | -2,938 | -8 | -498 | -497 | -575 |
| Accounts payable and accrued liabilities | 2,570 | 1,188 | -1,100 | 150 | 888 |
| Other Working Capital | 16,360 | -15,636 | -554 | 3,228 | 3,842 |
| Other Operating Activity | 22,938 | 8,463 | 24,979 | 37,599 | 72,272 |
| Operating Cash Flow | $-171,724 | $-152,109 | $-63,381 | $-48,780 | $-38,593 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -83,493 | -84,588 | -94,770 | 142,867 | -107,112 |
| PPE Investments | -1,669 | -4,087 | -12,690 | -34,815 | -6,560 |
| Purchase Of Investment | 0 | -3 | -723 | -8,500 | N/A |
| Sale Of Investment | 65,350 | 109,730 | 165,284 | N/A | N/A |
| Other Investing Activity | 0 | -2,500 | 0 | 0 | 0 |
| Investing Cash Flow | $-19,812 | $18,552 | $57,101 | $99,552 | $-113,672 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 150,002 | 47,670 | N/A | N/A | N/A |
| Debt Repayment | 0 | N/A | -477 | -19,932 | -32 |
| Common Stock Issued | 1,176 | 69,237 | 57 | 1,215 | 1,425 |
| Common Stock Repurchased | N/A | -2,501 | -228 | -15,227 | -15,847 |
| Other Financing Activity | -503 | -127 | -123 | -1,039 | -1,106 |
| Financing Cash Flow | $150,675 | $114,279 | $-771 | $-34,983 | $-15,560 |
| Exchange Rate Effect | -25 | -21 | N/A | N/A | N/A |
| Beginning Cash Position | 75,980 | 95,279 | 24,051 | 8,262 | 176,087 |
| End Cash Position | 35,094 | 75,980 | 17,000 | 24,051 | 8,262 |
| Net Cash Flow | $-40,886 | $-19,299 | $-7,051 | $15,789 | $-167,825 |
| Free Cash Flow | |||||
| Operating Cash Flow | -171,724 | -152,109 | -63,381 | -48,780 | -38,593 |
| Capital Expenditure | -1,669 | -4,287 | -13,102 | -34,815 | -6,560 |
| Free Cash Flow | -173,393 | -156,396 | -76,483 | -83,595 | -45,153 |